Literature DB >> 21130749

Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans.

Marie-Soleil Gauthier1, Elena L O'Brien, Sherman Bigornia, Melanie Mott, Jose M Cacicedo, X Julia Xu, Noyan Gokce, Caroline Apovian, Neil Ruderman.   

Abstract

Inflammation and infiltration of immune cells in white adipose tissue have been implicated in the development of obesity-associated insulin resistance. Likewise, dysregulation of the fuel-sensing enzyme AMP-activated protein kinase (AMPK) has been proposed as a pathogenetic factor for these abnormalities based on both its links to insulin action and its anti-inflammatory effects. In this study, we examined the relationships between AMPK activity, the expression of multiple inflammatory markers in visceral (mesenteric and omental) and abdominal subcutaneous adipose tissue, and whole-body insulin sensitivity in morbidly obese patients (BMI 48±1.9 kg/m(2)) undergoing gastric bypass surgery. AMPK activity was assessed by Western-blots (P-AMPK/T-AMPK) and mRNA levels of various markers of inflammation by qRT-PCR. Patients were stratified as insulin sensitive obese or insulin-resistant obese according to their HOMA-IR values. The results indicate that AMPK activity is lower in visceral than in subcutaneous abdominal adipose tissue of these patients and that this is associated with an increased expression of multiple inflammatory genes. They also revealed that AMPK activity is lower in adipose tissue of obese patients who are insulin resistant (HOMA-IR>2.3) than in BMI-matched insulin sensitive subjects. Furthermore, this difference was evident in all three fat depots. In conclusion, the data suggest that there are close links between reduced AMPK activity and inflammation in white adipose tissue, and whole-body insulin resistance in obese humans. Whether adipose tissue AMPK dysregulation is a causal factor for the development of the inflammation and insulin resistance remains to be determined. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21130749      PMCID: PMC3061625          DOI: 10.1016/j.bbrc.2010.11.127

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  38 in total

1.  Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation.

Authors:  Eva Tomas; Tsu-Shuen Tsao; Asish K Saha; Heather E Murrey; Cheng cheng Zhang Cc; Samar I Itani; Harvey F Lodish; Neil B Ruderman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-27       Impact factor: 11.205

Review 2.  Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes.

Authors:  N B Ruderman; J M Cacicedo; S Itani; N Yagihashi; A K Saha; J M Ye; K Chen; M Zou; D Carling; G Boden; R A Cohen; J Keaney; E W Kraegen; Y Ido
Journal:  Biochem Soc Trans       Date:  2003-02       Impact factor: 5.407

Review 3.  Characterizing the profile of obese patients who are metabolically healthy.

Authors:  V Primeau; L Coderre; A D Karelis; M Brochu; M-E Lavoie; V Messier; R Sladek; R Rabasa-Lhoret
Journal:  Int J Obes (Lond)       Date:  2010-10-26       Impact factor: 5.095

4.  Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation.

Authors:  Yasuo Ido; David Carling; Neil Ruderman
Journal:  Diabetes       Date:  2002-01       Impact factor: 9.461

5.  The obese healthy paradox: is inflammation the answer?

Authors:  Nuria Barbarroja; Rosario López-Pedrera; Maria Dolores Mayas; Eduardo García-Fuentes; Lourdes Garrido-Sánchez; M Macías-González; Rajaa El Bekay; Antonio Vidal-Puig; Francisco J Tinahones
Journal:  Biochem J       Date:  2010-08-15       Impact factor: 3.857

Review 6.  Macrophages, inflammation, and insulin resistance.

Authors:  Jerrold M Olefsky; Christopher K Glass
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

7.  Adipose tissue inflammation and insulin resistance: all obese humans are not created equal.

Authors:  Marie-Soleil Gauthier; Neil B Ruderman
Journal:  Biochem J       Date:  2010-09-01       Impact factor: 3.857

8.  Differences in AMPK expression between subcutaneous and visceral adipose tissue in morbid obesity.

Authors:  O Martínez-Agustin; J J Hernández-Morante; E Martínez-Plata; F Sánchez de Medina; M Garaulet
Journal:  Regul Pept       Date:  2010-05-10

9.  Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK.

Authors:  Mandeep P Gaidhu; Nicole M Anthony; Prital Patel; Thomas J Hawke; Rolando B Ceddia
Journal:  Am J Physiol Cell Physiol       Date:  2010-01-27       Impact factor: 4.249

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  82 in total

Review 1.  Phosphatidylinositol-3,4,5-triphosphate and cellular signaling: implications for obesity and diabetes.

Authors:  Prasenjit Manna; Sushil K Jain
Journal:  Cell Physiol Biochem       Date:  2015-02-11

2.  Naringin Improves Neuronal Insulin Signaling, Brain Mitochondrial Function, and Cognitive Function in High-Fat Diet-Induced Obese Mice.

Authors:  Dongmei Wang; Junqiang Yan; Jing Chen; Wenlan Wu; Xiaoying Zhu; Yong Wang
Journal:  Cell Mol Neurobiol       Date:  2015-05-05       Impact factor: 5.046

Review 3.  What distinguishes adipose tissue of severely obese humans who are insulin sensitive and resistant?

Authors:  X Julia Xu; Walter J Pories; Lynis G Dohm; Neil B Ruderman
Journal:  Curr Opin Lipidol       Date:  2013-02       Impact factor: 4.776

Review 4.  BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.

Authors:  Dequina A Nicholas; Guillaume Andrieu; Katherine J Strissel; Barbara S Nikolajczyk; Gerald V Denis
Journal:  Cell Mol Life Sci       Date:  2016-08-04       Impact factor: 9.261

Review 5.  Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.

Authors:  Sandeep Rana; Elizabeth C Blowers; Amarnath Natarajan
Journal:  J Med Chem       Date:  2014-08-28       Impact factor: 7.446

6.  TBK1 at the Crossroads of Inflammation and Energy Homeostasis in Adipose Tissue.

Authors:  Peng Zhao; Kai In Wong; Xiaoli Sun; Shannon M Reilly; Maeran Uhm; Zhongji Liao; Yuliya Skorobogatko; Alan R Saltiel
Journal:  Cell       Date:  2018-02-08       Impact factor: 41.582

7.  Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.

Authors:  Neda Rasouli; Philip A Kern; Steven C Elbein; Neeraj K Sharma; Swapan K Das
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

Review 8.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

9.  Daily Overfeeding from Protein and/or Carbohydrate Supplementation for Eight Weeks in Conjunction with Resistance Training Does not Improve Body Composition and Muscle Strength or Increase Markers Indicative of Muscle Protein Synthesis and Myogenesis in Resistance-Trained Males.

Authors:  Mike Spillane; Darryn S Willoughby
Journal:  J Sports Sci Med       Date:  2016-02-23       Impact factor: 2.988

Review 10.  Metabolically healthy obesity--does it exist?

Authors:  Patchaya Boonchaya-anant; Caroline M Apovian
Journal:  Curr Atheroscler Rep       Date:  2014-10       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.